Core Viewpoint - The Gross Law Firm is notifying shareholders of Inovio Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements and deficiencies in manufacturing related to the company's CELLECTRA device and its lead product candidate, INO-3107 [1][3]. Group 1: Allegations - The complaint alleges that during the class period from October 10, 2023, to December 26, 2025, Inovio issued materially false and misleading statements [3]. - Specific allegations include deficiencies in manufacturing for Inovio's CELLECTRA device, which impacted the likelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [3]. - It is claimed that Inovio lacked sufficient information to justify the eligibility of INO-3107 for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is April 7, 2026, and participation does not require appointment as a lead plaintiff [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Corcept Therapeutics Incorporated regarding a class action lawsuit related to misleading statements about the FDA's feedback on the relacorilant NDA process [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from October 31, 2024, to December 30, 2025 [3]. - Allegations include that Corcept concealed concerns from the FDA regarding the adequacy of the relacorilant effectiveness program and the design of the GRACE study, leading to materially false or misleading statements about the NDA approval expectations [3]. - The deadline for shareholders to register for the class action is April 21, 2026, and participation does not require a lead plaintiff appointment [4]. Group 2: Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible business conduct [5]. - The firm offers portfolio monitoring software for registered shareholders to receive updates throughout the case lifecycle [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Aquestive Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's New Drug Application for Anaphylm, which led to a significant drop in stock price [1][3]. Group 1: Allegations and Impact - Shareholders who purchased shares of AQST between June 16, 2025, and January 8, 2026, are encouraged to contact the firm for possible lead plaintiff appointment [1][4]. - The complaint alleges that Aquestive provided positive statements while concealing material adverse facts about the Anaphylm NDA, particularly regarding human factors in its use and deployment [3]. - Following the announcement of deficiencies identified by the FDA on January 9, 2026, the stock price of Aquestive fell from $6.21 to $3.91, a decline of over 37% in one day [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is May 4, 2026, and they will be enrolled in a portfolio monitoring software for updates [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Ultragenyx Pharmaceutical Inc. regarding a class action lawsuit due to misleading statements about the company's drug setrusumab and its clinical study results [1][3]. Group 1: Allegations and Impact - The allegations state that Ultragenyx provided overly positive statements while concealing material adverse facts about setrusumab's potential and the risks in study protocols [3]. - The Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates, contrary to management's claims [3]. - Following the announcement of the study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 to $19.72, a decline of approximately 42.32% in one day [3]. Group 2: Class Action Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is April 6, 2026, and there is no cost to participate in the case [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Market Overview - US equities finished lower, with S&P 500 futures down 0.4% and Nasdaq 100 futures down 0.6%, marking a potential fourth consecutive week of losses, the longest losing streak in a year [1] - Brent crude oil prices declined 0.7% to around $108 after earlier gains, while the VIX rose to around 25, indicating increased market volatility [1] - The US Dollar increased by 0.2% as markets adjusted expectations for Fed rate cuts, now pricing in less than 5 basis points for the year, down from 60 basis points last month [1] Corporate News - FedEx shares rose 7% after raising its full-year profit forecast, indicating successful restructuring efforts [5] - Figs Inc. gained 6% following an upgrade to outperform by Oppenheimer, suggesting a sustained recovery [5] - Planet Labs saw a 14% increase in shares after reporting revenue that exceeded analyst estimates [5] - Super Micro Computer Inc. shares fell 26% after a co-founder was charged with illegally diverting Nvidia-powered servers to China [5] - Alibaba and Tencent lost a combined $66 billion in market value after failing to present clear AI profit strategies [3][14] Geopolitical Impact - The ongoing conflict in Iran is affecting global market sentiment, with rising oil prices and geopolitical tensions leading to increased volatility [4][6] - Traders are preparing for a significant options expiry event, with $5.7 trillion in notional options set to expire, which could lead to abrupt price swings [7][9] - The ECB and BoE held rates steady but indicated readiness to act if inflation pressures increase due to the Iran conflict, leading to a sell-off in bonds [41][42] Sector Performance - The construction sector outperformed while energy stocks lagged amid rising crude oil prices [13] - Asian markets reacted negatively to disappointing earnings from tech companies, particularly Alibaba, which reported a 67% drop in Q3 net income [14][23] - The energy sector is under pressure as Brent crude prices are projected to rise significantly if geopolitical tensions persist [19][39]

Group 1 - Immunic, Inc. (NASDAQ:IMUX) has received a key patent from the European Patent Office for its lead asset, vidofludimus calcium, which is expected to provide protection in Europe until 2038, with potential extension to 2043 through a Supplementary Protection Certificate [1][2] - The patent claims cover vidofludimus and its various forms, ensuring broad protection across all label-relevant dosing regimens, not limited to a single formulation [2] - H.C. Wainwright has lowered its price target for Immunic, Inc. to $5 from $8 while maintaining a Buy rating, indicating a reassessment of the company's valuation [3]

Core Insights - KalVista Pharmaceuticals, Inc. has announced the acceptance of five abstracts for presentation at the 2026 Global Angioedema Leadership Conference in Madrid, Spain [1] - One of the accepted abstracts is a late-breaking submission, which will be presented during a poster session and as an oral presentation [1] Company Developments - The conference will take place from March 26–29, 2026, highlighting the company's ongoing engagement in the angioedema research community [1] - The specific details of the late-breaking abstract presentation are scheduled for March 27 and March 28 at 11:50 am CET [1]

Core Viewpoint - Aquestive Therapeutics, Inc. has appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will remain as Corporate Secretary [1][5] Company Leadership Changes - Thomas A. Zalewski brings extensive experience in life sciences law and has previously served as a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP [1][2] - Lori J. Braender has served as Chief Legal Officer and Chief Compliance Officer since September 2018 and will continue as Corporate Secretary after her transition [3][5] Compensation and Inducement - Mr. Zalewski will receive an equity award of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options as part of his inducement to join the company [4] - The equity awards will vest over three years, with 25% vesting after the first and second anniversaries, and 50% on the third anniversary [4] Company Overview - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, operating as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [6] - The company is known for its PharmFilm® technology and is advancing Anaphylm™, the first oral epinephrine rescue medication, towards FDA approval [6]

Core Insights - The pharmaceutical industry remains attractive for long-term investments due to the constant demand for innovative medicines, despite potential volatility from clinical setbacks and patent expirations [1] Eli Lilly - Eli Lilly is a leading player in the chronic weight management drug market, primarily due to its product tirzepatide, which is approved for diabetes, weight loss, and obstructive sleep apnea [3][4] - Tirzepatide is projected to generate annual sales of approximately $62 billion by 2030, marking a peak in the pharmaceutical industry [4] - Eli Lilly has a market capitalization of $867 billion, with a gross margin of 83.04% and a dividend yield of 0.68% [6] Vertex Pharmaceuticals - Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis drug market, addressing the genetic causes of the disease, which leads to consistent revenue and earnings [7] - The cystic fibrosis patient population is growing at a compound annual rate of 3% from 2020 to 2025, and existing patients are living longer [7] - Vertex is diversifying its product lineup beyond cystic fibrosis, with recent approvals for acute pain and blood-related disorders, and strong phase 3 results for a new investigational medicine [9] Pfizer - Pfizer's stock is currently undervalued, trading at 9.3 times forward earnings compared to the healthcare sector average of 17.4 [10] - The company has a robust pipeline with over 20 phase 3 studies planned, which could lead to new product launches and improved financial results [12] - Pfizer offers an attractive dividend yield of over 6.3%, making it a solid option for long-term income seekers [13]

Core Viewpoint - The expiration of the core patent for Semaglutide on March 20 marks the beginning of a new phase for the GLP-1 industry in China, shifting the focus from legal barriers to market competition and commercialization strategies [2][3]. Group 1: Market Dynamics - The expiration of the patent does not guarantee the immediate availability of generic drugs; the actual competition will depend on regulatory approval, production capabilities, commercialization speed, and pricing strategies [3]. - Currently, ten domestic companies are in the application stage for Semaglutide, indicating a collective race rather than a single breakthrough [5]. - The competition will not solely be based on pricing but will also involve consistency, supply stability, channel capabilities, and the speed of advancing indications [5]. Group 2: Approval Timeline - The companies most likely to receive approval first for diabetes indications are Jiuyuan Gene and Lizhu Group, with Jiuyuan being the first to submit its application [6]. - Jiuyuan's application for diabetes indication was accepted on April 2, 2024, while Lizhu's application was accepted on June 13, 2024 [6]. - The market expects the first diabetes indication approvals to be granted by the second half of 2026, while weight management indications may not see significant approvals until after 2027 [8]. Group 3: Pricing Strategies - A price war is anticipated, with the original drug already showing price reductions, indicating a preemptive price defense strategy in the GLP-1 market [9]. - The diabetes indication is expected to enter a more intense price competition phase post-approval, while the weight management indication may not see drastic price drops initially due to brand and consumer factors [9]. - The overall trend suggests that Semaglutide will not maintain its previous high-price, scarce, and strong brand premium status in the Chinese market [9].